Cargando…

A fast screening method for the detection of CERA in dried blood spots

Continuous erythropoietin receptor activator (CERA) is a third‐generation erythropoiesis‐stimulating agent that was developed for the treatment of anemia. However, misuse of CERA for doping in endurance sports has been reported. Previous studies have shown blood as the matrix of choice for the detec...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocca, Angela, Martin, Laurent, Kuuranne, Tiia, Ericsson, Magnus, Marchand, Alexandre, Leuenberger, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540874/
https://www.ncbi.nlm.nih.gov/pubmed/34380180
http://dx.doi.org/10.1002/dta.3142
_version_ 1784803800483102720
author Rocca, Angela
Martin, Laurent
Kuuranne, Tiia
Ericsson, Magnus
Marchand, Alexandre
Leuenberger, Nicolas
author_facet Rocca, Angela
Martin, Laurent
Kuuranne, Tiia
Ericsson, Magnus
Marchand, Alexandre
Leuenberger, Nicolas
author_sort Rocca, Angela
collection PubMed
description Continuous erythropoietin receptor activator (CERA) is a third‐generation erythropoiesis‐stimulating agent that was developed for the treatment of anemia. However, misuse of CERA for doping in endurance sports has been reported. Previous studies have shown blood as the matrix of choice for the detection of CERA, due to its high molecular weight. The use of dried blood spots (DBSs) for anti‐doping purposes constitutes a complementary approach to the standard urine and venous blood matrices and could facilitate sample collection and increase the number of blood samples available for analysis due to reduced costs of sample collection and transport. Here, we investigated whether CERA could be indirectly detected in extracts of single DBSs using an erythropoietin‐specific immunoassay that is capable of providing results within approximately 2 h. Reconstituted DBS samples were prepared from mixtures of red blood cell pellets and serum samples. The samples were collected in a previous clinical study in which six healthy volunteers were injected with a single, 200 μg dose of CERA. Using a commercially available ELISA kit, CERA was detected in the DBSs with a detection window of up to 20 days post‐injection. Furthermore, in order to demonstrate the fitness‐for‐purpose, three authentic doping control serum samples, which were identified as containing CERA, were analyzed by the presented methodological approach on DBS. The testing procedure described here could be used as a fast and cost‐effective method for the detection of CERA abuse in sport.
format Online
Article
Text
id pubmed-9540874
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95408742022-10-14 A fast screening method for the detection of CERA in dried blood spots Rocca, Angela Martin, Laurent Kuuranne, Tiia Ericsson, Magnus Marchand, Alexandre Leuenberger, Nicolas Drug Test Anal Special Issue ‐ Short Communication Continuous erythropoietin receptor activator (CERA) is a third‐generation erythropoiesis‐stimulating agent that was developed for the treatment of anemia. However, misuse of CERA for doping in endurance sports has been reported. Previous studies have shown blood as the matrix of choice for the detection of CERA, due to its high molecular weight. The use of dried blood spots (DBSs) for anti‐doping purposes constitutes a complementary approach to the standard urine and venous blood matrices and could facilitate sample collection and increase the number of blood samples available for analysis due to reduced costs of sample collection and transport. Here, we investigated whether CERA could be indirectly detected in extracts of single DBSs using an erythropoietin‐specific immunoassay that is capable of providing results within approximately 2 h. Reconstituted DBS samples were prepared from mixtures of red blood cell pellets and serum samples. The samples were collected in a previous clinical study in which six healthy volunteers were injected with a single, 200 μg dose of CERA. Using a commercially available ELISA kit, CERA was detected in the DBSs with a detection window of up to 20 days post‐injection. Furthermore, in order to demonstrate the fitness‐for‐purpose, three authentic doping control serum samples, which were identified as containing CERA, were analyzed by the presented methodological approach on DBS. The testing procedure described here could be used as a fast and cost‐effective method for the detection of CERA abuse in sport. John Wiley and Sons Inc. 2021-08-21 2022-05 /pmc/articles/PMC9540874/ /pubmed/34380180 http://dx.doi.org/10.1002/dta.3142 Text en © 2021 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Special Issue ‐ Short Communication
Rocca, Angela
Martin, Laurent
Kuuranne, Tiia
Ericsson, Magnus
Marchand, Alexandre
Leuenberger, Nicolas
A fast screening method for the detection of CERA in dried blood spots
title A fast screening method for the detection of CERA in dried blood spots
title_full A fast screening method for the detection of CERA in dried blood spots
title_fullStr A fast screening method for the detection of CERA in dried blood spots
title_full_unstemmed A fast screening method for the detection of CERA in dried blood spots
title_short A fast screening method for the detection of CERA in dried blood spots
title_sort fast screening method for the detection of cera in dried blood spots
topic Special Issue ‐ Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540874/
https://www.ncbi.nlm.nih.gov/pubmed/34380180
http://dx.doi.org/10.1002/dta.3142
work_keys_str_mv AT roccaangela afastscreeningmethodforthedetectionofceraindriedbloodspots
AT martinlaurent afastscreeningmethodforthedetectionofceraindriedbloodspots
AT kuurannetiia afastscreeningmethodforthedetectionofceraindriedbloodspots
AT ericssonmagnus afastscreeningmethodforthedetectionofceraindriedbloodspots
AT marchandalexandre afastscreeningmethodforthedetectionofceraindriedbloodspots
AT leuenbergernicolas afastscreeningmethodforthedetectionofceraindriedbloodspots
AT roccaangela fastscreeningmethodforthedetectionofceraindriedbloodspots
AT martinlaurent fastscreeningmethodforthedetectionofceraindriedbloodspots
AT kuurannetiia fastscreeningmethodforthedetectionofceraindriedbloodspots
AT ericssonmagnus fastscreeningmethodforthedetectionofceraindriedbloodspots
AT marchandalexandre fastscreeningmethodforthedetectionofceraindriedbloodspots
AT leuenbergernicolas fastscreeningmethodforthedetectionofceraindriedbloodspots